Displaying items by tag: department of neurology

For a second summer, Maria Onatunde traveled to UAB from Florida to participate in UAB's PARAdiGM program, which offers in-depth research experience for undergraduates from disadvantaged and minority backgrounds.

A UAB study sheds light on and suggests a target for treatment of a variant of Guillain-Barré syndrome.

An intriguing paper by Harvard researchers has everyone talking, thanks to widespread media coverage. Neuroscientist Erik Roberson, M.D., Ph.D., co-director of UAB's Center for Neurodegeneration and Experimental Therapeutics, offers his thoughts on a discovery gone viral.
Results show that JAK/STAT pathway inhibitors may be a new class of therapeutic treatments for patients with Parkinson’s disease. Acting by reducing inflammation, they prevent neurodegeneration in animal models and may be an important new approach to slow progression of the disease.
UAB joins with leading Parkinson’s disease organizations for a Birmingham conference.
Preliminary results from UAB’s CBD oil studies show benefit in seizure control in some patients.
A key role for microRNA-155 in brain inflammation and neurodegeneration makes it both a potential therapeutic target and a biomarker for this progressive disorder.
Alabama ALS chapter honors UAB’s Peter King with Spirit of Lou Gehrig Award.
UAB-led research shows how methylating an RNA binding protein leads to alternative RNA splicing. Mutant enzymes are often found in blood cancers.
Best of 2015 2The UAB studies are designed to test the safety and tolerability of CBD oil in patients with intractable seizures. CBD oil, a derivative of the cannabis plant, is delivered orally as an oily liquid.
The Alzheimer’s plaques that accumulate around brain cells also congregate along the walls of blood vessels, according to UAB research, and that may contribute to cognitive issues.
Engineers, physicians, computer scientists and statisticians will collaborate to research and apply big data in the health care, industrial and smart cities fields.
A multisite study led by UAB has found the first biomarker for the onset of seizures in infants with tuberous sclerosis.
UAB's strengths in clinical care and research are powering an interdisciplinary expedition into largely uncharted territory: neuroinflammatory mechanisms in Parkinson's disease.

UAB’s Roberson wins young investigator award from the American Neurological Association.

Page 7 of 11